NOW APPROVED:  Xeomin is now the first and only neurotoxin without unnecessary proteins approved for upper facial lines.*

LEARN MORE
×

Physicians Clinical Results Glabellar Lines

PROVEN PERFORMANCE FOR UPPER FACIAL LINES

With nearly 15 years of clinical and global experience, only Xeomin® has been studied in 2 pivotal clinical trials simultaneously treating 2 key areas of the upper face: forehead lines, frown lines, and crow’s feet.

Customize treatment using up to 64 Units to create your
3-2-1 Upper Facial Lines Treatment Plan:

UPPER FACIAL LINES CLINICAL DATA

Primary Endpoint: Xeomin met the primary endpoint of Treatment Success at Day 30 (composite endpoint of investigator and subject assessment, none or mild and at least two-grade improvement on MAS at maximum contraction)

SELECT SECONDARY ENDPOINTS

Investigator-assessed Treatment Success at Day 30 (score of none or mild on MAS at maximum contraction)

Not actual patient.

Subject-assessed Global Aesthetic Improvement Scale (GAIS)

97.7% and 98.3% of patients reported significant improvements in their upper facial lines by Day 30 in Study 1 and Study 2, respectively.

UFL Study Design. Xeomin’s efficacy and safety for simultaneous treatment of upper facial lines was established in a robust clinical trial program. Over 700 patients were enrolled in two Phase 3 randomized, double-blind, multicenter, placebo-controlled studies. Patients were followed for up to a year: Both studies followed patients for up to 120 days and included an open-label extension phase consisting of two additional 120-day treatment cycles.

GLABELLAR LINES CLINICAL DATA

In 2 randomized, double-blind, multicenter clinical trials, Xeomin was proven to temporarily improve the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.1-3 The most commonly observed adverse reaction incidence ≥2% of patients and greater than placebo) for Xeomin was headache (5.4%).

SIGNIFICANTLY SUPERIOR EFFICACY OVER PLACEBO

Bar chart comparing efficacy of Xeomin compared to placebo by patients and physicians

Composite treatment success: Study 1 – Xeomin 60%, Placebo 0%; Study 2 – Xeomin 48%, Placebo 0%

Up to 4 months of Xeomin efficacy and patient satisfaction in a majority of patients4,5

In a prospective, multicenter, randomized, double-blind, parallel trial, Xeomin was randomized 1:1 vs another neurotoxin. The study enrolled 250 healthy female patients (≥18 years old) with glabellar lines of at least moderate severity at maximum frown. Xeomin demonstrated comparable efficacy and duration up to four months. Patients were classified as responders only if they had a ≥1 point improvement from the baseline on the Facial Wrinkle Scale (FWS) at maximum frown, as assessed by the independent review panel using subject photographs at one month post treatment.

EFFICACY ASSESSED BY INDEPENDENT REVIEW PANEL

Bar chart comparing efficacy of Xeomin to Botox on frown lines by independant panel

EFFICACY ASSESSED BY TREATING PHYSICIAN

Bar chart comparing efficacy of Xeomin to Botox on frown lines by physicians

PATIENT SATISFACTION

Bar chart comparing satisfaction of Xeomin to Botox on frown lines by patient
QUESTIONS? CONNECT WITH A SALES REPRESENTATIVE

INDICATIONS AND USAGE

XEOMIN® (incobotulinumtoxinA) for injection, for intramuscular use is indicated for the temporary improvement in the appearance of moderate to severe upper facial lines in adults (glabellar lines with corrugator and/or procerus muscle activity [GL], horizontal forehead lines associated with frontalis muscle activity [HFL], and lateral canthal lines associated with orbicularis oculi activity [LCL].)

IMPORTANT SAFETY INFORMATION

WARNING: DISTANT SPREAD OF TOXIN EFFECT
See full prescribing information for complete BOXED WARNING.

 
The effects of XEOMIN and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. The risk of symptoms is probably greatest in children treated for spasticity but symptoms can also occur in adults, particularly in those patients who have underlying conditions that would predispose them to these symptoms.

CONTRAINDICATIONS

Hypersensitivity reactions have been reported with botulinum toxin products (anaphylaxis, serum sickness, urticaria, soft tissue edema, and dyspnea). If serious and/or immediate hypersensitivity reactions occur further injection of XEOMIN should be discontinued and appropriate medical therapy immediately instituted. XEOMIN is contraindicated in patients with known hypersensitivity to any botulinum toxin preparation or to any of the components in the formulation.

Use in patients with an infection at the injection site could lead to severe local or disseminated infection. XEOMIN is contraindicated in the presence of infection at the proposed injection site(s).

WARNINGS AND PRECAUTIONS

  • Treatment with XEOMIN and other botulinum toxin products can result in swallowing or breathing difficulties. Patients with pre-existing swallowing or breathing difficulties may be more susceptible to these complications. When distant effects occur, additional respiratory muscles may be involved. Patients may require immediate medical attention should they develop problems with swallowing, speech, or respiratory disorders. Dysphagia may persist for several months, which may require use of a feeding tube. Aspiration may result from severe dysphagia [See BOXED WARNING].
  • The potency Units and Units of biological activity of XEOMIN are specific to their respective preparation and assay method utilized, and thus cannot be compared or converted into Units of any other botulinum toxin products.
  • Individuals with peripheral motor neuropathic diseases, amyotrophic lateral sclerosis, or neuromuscular junctional disorders (e.g., myasthenia gravis or Lambert-Eaton syndrome) should be monitored particularly closely when given botulinum toxin. Patients with neuromuscular disorders may be at increased risk of clinically significant effects including severe dysphagia and respiratory compromise from typical doses of XEOMIN.
  • Upper Facial Lines: Do not exceed the recommended dosage and frequency of administration of XEOMIN.
    • GL: To reduce the complication of ptosis avoid injection near the levator palpebrae superioris, particularly in patients with larger brow depressor complexes. Corrugator injections should be placed at least 1 cm above the bony supraorbital ridge.
    • HFL: Treat HFL in conjunction with GL to minimize the potential for brow ptosis.
    • LCL: Avoid injections too close to the zygomaticus major muscle to prevent lip ptosis.
  • Use caution when XEOMIN is used in patients who have marked facial asymmetry, with surgical alterations to the facial anatomy, pre-existing eyelid or eyebrow ptosis, when excessive weakness or atrophy is present in the target muscles, excessive dermatochalasis, deep dermal scarring, thick sebaceous skin (e.g., the inability to substantially lessen glabellar lines even by physically spreading them apart).
  • Caution should be taken when XEOMIN is used where the targeted muscle shows excessive weakness or atrophy.
  • XEOMIN contains human serum albumin. Based on effective donor screening and product manufacturing processes, it carries an extremely remote risk for transmission of viral diseases and variant Creutzfeldt-Jakob disease (vCJD). There is a theoretical risk for transmission of Creutzfeldt-Jakob disease (CJD), but if that risk actually exists, the risk of transmission would also be considered extremely remote. No cases of transmission of viral diseases, CJD or vCJD have ever been reported for albumin.

ADVERSE REACTIONS

Upper Facial Lines (Glabellar Lines, Horizontal Forehead Lines, and Lateral Canthal Lines): The most commonly observed adverse reaction (incidence ≥ 1% of patients and greater than placebo) for XEOMIN was injection site bruising (2%).

DRUG INTERACTIONS

Co-administration of XEOMIN and aminoglycoside or other agents interfering with neuromuscular transmission, (e.g., muscle relaxants), should only be performed with caution as these agents may potentiate the effect of the toxin.

Use of anticholinergic drugs after administration of XEOMIN may potentiate systemic anticholinergic effects. The effect of administering different botulinum toxin products at the same time or within several months of each other is unknown. Excessive neuromuscular weakness may be exacerbated by administration of another botulinum toxin prior to the resolution of the effects of a previously administered botulinum toxin.

USE IN PREGNANCY

There are no adequate data on the developmental risk associated with the use of XEOMIN in pregnant women. XEOMIN should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

PEDIATRIC USE

Safety and effectiveness of XEOMIN for upper facial lines in patients less than 18 years of age have not been established.

© 2024 Merz North America, Inc. All rights reserved. MERZ AESTHETICS and XEOMIN are registered trademarks of Merz Pharma GmbH & Co. KGaA in the U.S.

References

  1. Xeomin® (incobotulinumtoxinA) for injection, for intramuscular use. Prescribing Information. Merz Pharmaceuticals, LLC, 2020.
  2. Carruthers A, Carruthers J, Heinz M, et al. Multicentre, randomized phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013;39:551-558.
  3. Hanke CW, Narins RS, Brandt F, et al. A randomized, placebo-controlled, double-blind phase III trial investigating the efficacy and safety of incobotulinumtoxinA in the treatment of glabellar frown lines using a stringent composite endpoint. Dermatol Surg. 2013;39(6):891-899.
  4. Data on File, Merz North America.
  5. Kane MA, Gold MH, Coleman WP, et al. A randomized, double-blind trial to investigate the equivalence of incobotulinumtoxinA and onabotulinumtoxinA for glabellar frown lines. Dermatol Surg. 2015;41(11):1319.